Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 12:55 AM ET

Biotechnology

Company Overview of Oryzon Genomics S.A.

Company Overview

Oryzon Genomics S.A., a biopharmaceutical company, develops and commercializes biomarkers identified through genomics and proteomics in the fields of diagnostics, personalized medicine, and therapy. Its products pipeline comprises GynEC-DX, a diagnostic test for endometrial cancer; ColoBRAF, a genetic test that verifies the presence of the BRAF-V600E mutation in MSI-H tumors; and Cxbladder, a non-invasive bladder cancer diagnostic test. The company also develops small molecules and monoclonal antibodies for various indications, including leukemia and other cancers, PD/AD and other dementias, Huntington, viral infections, squamous cell cancer, prostate cancer, and endometrial cancer. In addit...

Sant Ferran 74

Cornellà de Llobregat

Barcelona,  08940

Spain

Founded in 2000

Phone:

34 93 515 13 13

Fax:

34 93 377 40 28

Key Executives for Oryzon Genomics S.A.

Co-Founder, Chairman, Chief Executive Officer, President and Member of Financial Advisory Board
Co-Founder, Scientific Director and Director
Global Chief Financial Officer, Executive Vice President, Director and Chairman of Audit Committee
Chief Intellectual Property Officer
Director of Business Development
Compensation as of Fiscal Year 2015.

Oryzon Genomics S.A. Key Developments

Oryzon Genomics S.A. Proposes Amendments to its Articles of Association

Oryzon Genomics S.A. at the Annual General Meeting to be held on June 30, 2015, proposed amendment of Articles 16 and 23 to adapt to changes concerning the system of the General Meeting and its powers, amendment of Articles 20a, 22 and 24 to adapt to changes concerning the system the Board of Directors and the status of its directors and amendment of article 18 to include a technical improvement.

Oryzon Genomics S.A., Annual General Meeting, Jun 30, 2015

Oryzon Genomics S.A., Annual General Meeting, Jun 30, 2015., at 10:00 Central European Standard Time. Location: Cornellà de Llobregat. Agenda: To consider and approve abridged financial statements and approval, if any, of the proposed application of results for the fiscal year ended December 31, 2014; to consider amendment to Articles 16, 23, 20a, 22 and 24; to consider amendment of article 18 to include a technical improvement; to consider approval, if any, of the capital increase by raising the value par value of shares currently outstanding; to consider capital increase by issuing new excluding shares and preferential subscription right; to consider ratification of the contract signed by the company accepting the conditions for Grant funding in biotechnology; to consider agreement approved by the Board of Directors Society on the relationship of Mr. and Mrs. Carlos Buesa. Tamara Maes with the company; and to consider delegation of powers point.

Oryzon Genomics SA Appoints Greg Weaver as Executive Vice President and Global Chief Financial Officer

Oryzon Genomics SA announced the appointment of Gregory L. Weaver as executive vice president and chief financial officer, effective January 12, 2015. Weaver will report directly to Carlos Buesa, president and chief executive officer of Oryzon, and will be based at Oryzon's U.S. headquarters, located at 245 First Street in Cambridge, MA. Weaver has served as CFO Fibrocell Science. Previous to Fibrocell, Weaver was CFO at Celsion Corp, Poniard Pharmaceuticals and Sirna Therapeutics. He also currently serves as non-executive director of Egalet Corporation and Atossa Genetics. Oryzon's Mr. Enric Rello will remain as CFO in Spain and will continue as part of Oryzon's senior management team to support the company's financial operations in Spain.

Similar Private Companies By Industry

Company Name Region
Fina Biotech, S.L. Europe
Enemce Pharma S.L. Europe
MDRenal LIFE SCIENCES Europe
Digna Biotech S.L. Europe
Fresas Nuevos Materiales S.A. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oryzon Genomics S.A., please visit www.oryzon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.